Impact of reticulated platelets on antiplatelet response to thienopyridines is independent of platelet turnover

Summary

Reticulated platelets are associated with impaired antiplatelet response to thienopyridines. It is uncertain whether this interaction is caused by a decreased drug exposure due to high platelet turnover reflected by elevated levels of reticulated platelets or by intrinsic properties of reticulated platelets. This study sought to investigate if the impact of reticulated platelets on early antiplatelet response to thienopyridines is mainly caused by platelet turnover as previously suggested. Elective patients undergoing coronary intervention were randomised to loading with clopidogrel 600 mg or prasugrel 60 mg (n=200). Adenosine diphosphate (ADP)-induced platelet reactivity was determined by impedance aggregometry before, at 30, 60, 90, and 120 minutes and at day 1 after loading. Immature platelet count was assessed as marker of reticulated platelets by flow cytometry. Platelet reactivity increased with rising levels of immature platelet count in both groups. This effect was more distinctive in patients on clopidogrel as compared to patients on prasugrel. Overall, immature platelet count correlated well with on-treatment platelet reactivity at all timepoints (p < 0.001). These correlations did not change over time in the entire cohort as well as in patients treated with clopidogrel or prasugrel indicating an effect independent of platelet turnover (comparison of correlations 120 minutes/day 1: p = 0.64). In conclusion, the association of immature platelet count with impaired antiplatelet response to thienopyridines is similar early and late after loading. This finding suggests as main underlying mechanism another effect of reticulated platelets on thienopyridines than platelet turnover.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Immature platelets - reticulated platelets - clopidogrel - prasugrel - platelet reactivity

• References

• 1 Ault KA, Rinder HM, Mitchell J. et al. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombo-poiesis. Am J Clin Pathol 1992; 98: 637-646.
• 2 Grove EL, Hvas AM, Mortensen SB. et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 09: 185-191.
• 3 Thompson CB, Eaton KA, Princiotta SM. et al. Size dependent platelet subpopu-lations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 1982; 50: 509-519.
• 4 D’Souza C, Briggs C, Machin SJ. Platelets: the few, the young, and the active. Clin Lab Med 2015; 35: 123-131.
• 5 Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
• 6 Cesari F, Marcucci R, Gori AM. et al. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost 2013; 109: 846-853.
• 7 Ibrahim H, Schutt RC, Hannawi B. et al. Association of immature platelets with adverse cardiovascular outcomes. J Am Coll Cardiol 2014; 64: 2122-2129.
• 8 Guthikonda S, Alviar CL, Vaduganathan M. et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52: 743-749.
• 9 Perl L, Lerman-Shivek H, Rechavia E. et al. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myo-cardial infarction. J Am Coll Cardiol 2014; 63: 513-517.
• 10 Bernlochner I, Goedel A, Plischke C. et al. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. Eur Heart J 2015; 36: 3202-3210.
• 11 Wallentin L, Varenhorst C, James S. et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
• 12 Ernest 2nd CS, Small DS, Rohatagi S. et al. Population pharmacokinetics and phar-macodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodynam 2008; 35: 593-618.
• 13 Hoffmann JJ. Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 2014; 52: 1107-1117.
• 14 Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995; 23: 996-1001.
• 15 Hoffmann JJ. Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 2014; 52: 1107-1117.
• 16 Hochholzer W, Amann M, Titov A. et al. Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention: The ExcelsiorLOAD Trial. JACC Cardiovasc Interven 2015; 09: 219-227.
• 17 Sibbing D, Braun S, Morath T. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
• 18 Aradi D, Kirtane A, Bonello L. et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36: 1762-1771.
• 19 Tantry US, Bonello L, Aradi D. et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
• 20 Pons I, Monteagudo M, Lucchetti G. et al. Correlation between immature platelet fraction and reticulated platelets. Usefulness in the etiology diagnosis of thrombocytopenia. Eur J Haematol 2010; 85: 158-163.
• 21 Diedenhofen B, Musch J. cocor: a comprehensive solution for the statistical comparison of correlations. PLoS One 2015; 10: e0121945.
• 22 Hochholzer W, Trenk D, Fromm MF. et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopi-dogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-2434.
• 23 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
• 24 Rinder HM, Schuster JE, Rinder CS. et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91: 1288-1294.
• 25 McBane 2nd RD, Gonzalez C, Hodge DO. et al. Propensity for young reticulated platelet recruitment into arterial thrombi. J Thromb Thrombolysis 2014; 37: 148-154.
• 26 Eikelboom JW, Warkentin TE. Immature platelet count: part of the cardiologist’s complete blood count?. J Am Coll Cardiol 2014; 64: 2130-2132.
• 27 Hochholzer W, Valina CM, Bomicke T. et al. Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome. Thromb Haemost 2015; 114: 109-114.
• 28 Hoffmann K, Lutz DA, Strassburger J. et al. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor. J Thromb Haemost 2014; 12: 1898-1905.
• 29 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.